Pfizer PFEhas announced that the regulatory applications for its pipeline candidate, dacomitinib, have been accepted for review in both the United States and the EU. The company is looking to get the drug approved for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in patients with EGFR-activating mutations.
Notably, the FDA granted a priority review to dacomitinib with a response expected in September 2018.Pfizer's Lung Cancer Candidate Gets FDA's Priority Review
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться